Clinical reference Biomarker Directory
Back to directory

S100A8

Established

S100A8, as part of calprotectin, is a widely used noninvasive marker distinguishing IBD from irritable bowel syndrome.

Also known as Calprotectin (component) MRP8
In plain language

S100A8 is part of calprotectin, a stool test that helps tell inflammatory bowel disease apart from irritable bowel syndrome, similar to the lactoferrin test discussed earlier, and it's also used to check how well IBD treatment is working over time.

Biomarker & context

S100A8 is one of two proteins (with S100A9) that combine to form calprotectin, an inflammatory marker released by neutrophils; fecal calprotectin testing is a widely used noninvasive marker of intestinal inflammation.

What it indicates

Elevated fecal calprotectin (reflecting S100A8/A9) supports inflammatory bowel disease over irritable bowel syndrome in patients with GI symptoms, functioning similarly to fecal lactoferrin (discussed earlier) in helping avoid unnecessary invasive testing in low-risk patients.

Diagnosis & clinical testing

Measured via stool immunoassay; calprotectin is more widely used clinically than lactoferrin for this purpose, with well-established cutoffs distinguishing likely IBD from likely functional (non-inflammatory) bowel symptoms.

Guiding treatment

A low fecal calprotectin in a patient with IBS-type symptoms supports deferring colonoscopy, while an elevated result prompts endoscopic evaluation; calprotectin is also used to monitor treatment response and detect subclinical inflammation in established IBD patients.

Clinical significance

Also used to monitor treatment response and detect subclinical inflammation in patients with established IBD.

References
  1. General gastroenterology reference literature on fecal calprotectin in IBD diagnosis and monitoring.